Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Mountainfield Venture Partners is a venture capital organization founded by a team with extensive experience in biopharmaceutical leadership. Established in the United States, the firm focuses on building new companies around development-stage drug candidates aimed at transforming patient care. The organization specializes in forming companies around in-licensed drug candidates and assembling world-class leadership teams, supported by capital raises from top-tier life science institutional investors.
Currently, Mountainfield has co-founded over 15 venture-backed life sciences companies, leading to six NASDAQ IPOs and eight FDA-approved drug products. The firm operates exclusively within the biopharmaceutical sector, leveraging its team's extensive experience in both small start-up biotechnology firms and multinational pharmaceutical companies.
Mountainfield Venture Partners invests primarily in the biopharmaceutical sector, concentrating on development-stage drug candidates. The firm emphasizes the creation of companies that leverage in-licensed drug candidates, aiming to establish operational strategies informed by its team's extensive industry experience. This approach allows Mountainfield to identify promising drug candidates and build companies that can effectively bring these innovations to market.
The organization invests at the seed, Series A, and Series B stages, focusing on startups that demonstrate potential for significant impact in healthcare. Mountainfield seeks founders with a strong vision and the capability to execute their plans, valuing deep industry knowledge and a commitment to advancing patient care.
Mountainfield Venture Partners has co-founded more than 15 venture-backed life sciences companies, achieving notable success in the biopharmaceutical sector. The firm has led to six NASDAQ IPOs and eight FDA-approved drug products. Key portfolio companies include:
Daniel Curran, MD - Managing Partner. Dr. Curran has extensive experience in biopharmaceutical leadership and has been instrumental in the formation of several successful life sciences companies.
David Socks - Managing Partner. Socks brings a wealth of knowledge in venture capital and has a strong track record in the biopharmaceutical sector.
Siyu Shi, MD - Vice President. Dr. Shi has a background in clinical development and has played a key role in advancing drug candidates through the pipeline.
Christian Fougner, MD, PhD - Vice President. Dr. Fougner specializes in drug development and has significant experience in both startup and multinational pharmaceutical environments.
Adam Ingber - Senior Associate. Ingber supports the investment team with research and analysis, focusing on emerging biopharmaceutical opportunities.
To pitch to Mountainfield Venture Partners, founders should visit their contact page at mountainfieldvp.com/contact. The firm prefers detailed decks that outline the business model, market opportunity, and team qualifications. Response times may vary, but founders are encouraged to provide thorough information to facilitate the review process.
In recent months, Mountainfield Venture Partners has continued to co-found and support venture-backed life sciences companies. The firm has maintained a strong track record, leading to six NASDAQ IPOs and eight FDA-approved drug products.
Specific recent activities include ongoing investments in development-stage drug candidates and the establishment of new partnerships within the biopharmaceutical sector.
What are Mountainfield Venture Partners' investment criteria?
Mountainfield focuses on the biopharmaceutical sector, specifically targeting development-stage drug candidates. The firm seeks to create companies around in-licensed drug candidates and values founders with strong industry knowledge.
How can I apply or pitch to Mountainfield?
Founders can pitch their ideas by visiting the Mountainfield Venture Partners contact page at mountainfieldvp.com/contact. The firm encourages detailed presentations that outline the business model, market potential, and team expertise.
What makes Mountainfield different from other venture capital firms?
Mountainfield's unique approach lies in its focus on forming companies around in-licensed drug candidates, leveraging extensive experience in both small biotech startups and large pharmaceutical firms. This strategy has led to a strong track record of successful IPOs and FDA approvals.
What is the geographic scope of Mountainfield's investments?
The firm invests exclusively in the United States, concentrating on the biopharmaceutical sector.
What is the typical check size for investments?
While specific check sizes are not disclosed, Mountainfield invests at the seed, Series A, and Series B stages, which typically involve varying amounts based on the company's needs and growth potential.
What kind of post-investment involvement does Mountainfield have?
Mountainfield actively participates in the development of its portfolio companies, often taking board positions and providing operational support to help guide the companies toward successful outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.